Publication: Estrategias terapéuticas frente a la esteatosis hepática no alcohólica: empleo de Resveratrol
Loading...
Official URL
Full text at PDC
Publication Date
2018-02
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
La enfermedad hepática del hígado graso no alcohólica es considerada como el componente hepático del síndrome metabólico y su prevalencia está aumentando rápidamente debido a su asociación con la obesidad y la resistencia a la insulina. Es necesario buscar tratamientos alternativos ya que los tratamientos actuales son
limitados. Estudios recientes han demostrado que el resveratrol tiene gran efecto terapéutico frente a las alteraciones hepáticas, siendo capaz de mejorarlas a través de la activación del AMPK, SIRT1 y disminución del SREBP-1c. Los mecanismos a través de los que actúa el resveratrol aumentan la beta-oxidación y disminuyen la lipogenesis de novo. El resveratrol tiene además un efecto antioxidante y antiinflamatorio que contribuyen a una mejora en el pronóstico junto con una adecuada prevención de la enfermedad. De acuerdo a los estudios in vivo e in vitro realizados, el resveratrol puede
disminuir la cantidad de lípidos acumulados en hígado, disminuir la resistencia a la insulina e incluso se ha visto que disminuye la masa corporal. Los ensayos clínicos realizados con el resveratrol son escasos y es necesario que en un futuro se lleven a cabo con pacientes apropiados para aclarar el verdadero impacto del tratamiento con resveratrol en aquellos que tienen diagnosticada una enfermedad hepática.
Non-alcoholic fatty liver disease is considered as the hepatic component of the metabolic disorder and its prevalence is increasing rapidly owing to its association with obesity and insulin resistance. It is necessary to look for alternative treatments since the current treatments are limited. Recent studies have shown that resveratrol has a great therapeutic effect against liver disorders, being able to improve them through the activation of AMPK, SIRT1 and decrease in SREBP-1c. Through its mechanisms of action, resveratrol is capable of increase beta-oxidation and decrease de novo lipogenesis. Resveratrol also has an antioxidant and anti-inflammatory effect that contributes to an improvement in prognosis along with an adequate prevention of the disease. According to in vivo and in vitro studies, resveratrol can decrease the accumulation of lipids in the liver, decrease insulin resistance and even decrease body mass. Clinical trials conducted with resveratrol are scarce and it is necessary that in the future they are carried out with appropriate patients to clarify the true impact of resveratrol treatment in those who have been diagnosed with liver disease.
Non-alcoholic fatty liver disease is considered as the hepatic component of the metabolic disorder and its prevalence is increasing rapidly owing to its association with obesity and insulin resistance. It is necessary to look for alternative treatments since the current treatments are limited. Recent studies have shown that resveratrol has a great therapeutic effect against liver disorders, being able to improve them through the activation of AMPK, SIRT1 and decrease in SREBP-1c. Through its mechanisms of action, resveratrol is capable of increase beta-oxidation and decrease de novo lipogenesis. Resveratrol also has an antioxidant and anti-inflammatory effect that contributes to an improvement in prognosis along with an adequate prevention of the disease. According to in vivo and in vitro studies, resveratrol can decrease the accumulation of lipids in the liver, decrease insulin resistance and even decrease body mass. Clinical trials conducted with resveratrol are scarce and it is necessary that in the future they are carried out with appropriate patients to clarify the true impact of resveratrol treatment in those who have been diagnosed with liver disease.